Andreopoulou, Eleni

Publications

Sort by

Co-Author Network

selected publications

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. Frontiers in oncology. 2023 Review GET IT
Times cited: 12
Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer. Breast cancer research and treatment. 2022 Academic Article GET IT
Times cited: 1
Alterations of the 70 kDa heat shock protein (HSP70) and sequestosome-1 (p62) in women with breast cancer. Scientific reports. 2021 Academic Article GET IT
Times cited: 2
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer. NPJ breast cancer. 2021 Academic Article GET IT
Times cited: 45
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast cancer research and treatment. 2021 Academic Article GET IT
Times cited: 10
Expert Discussion: HER2-Positive Breast Cancer. Breast care (Basel, Switzerland). 2021 Academic Article GET IT
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 46
Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. eLife. 2020 Academic Article GET IT
Times cited: 5
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. The oncologist. 2020 Academic Article GET IT
Times cited: 6
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. Frontiers in oncology. 2020 Academic Article GET IT
Times cited: 909
Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer. Oncology & hematology review. 2020 Academic Article GET IT
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. Cell reports. 2020 Academic Article GET IT
Times cited: 51
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 36
SET_ER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ breast cancer. 2019 Academic Article GET IT
Times cited: 1965
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 96
PARP Inhibitors in Breast Cancer: Why, How, and When?. Breast care (Basel, Switzerland). 2018 Academic Article GET IT
Times cited: 4
Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2018 Academic Article GET IT
Times cited: 16
Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. Clinical breast cancer. 2017 Academic Article GET IT
Times cited: 17
Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients. The American journal of surgical pathology. 2017 Academic Article GET IT
Times cited: 13
Therapeutic Advances and New Directions for Triple-Negative Breast Cancer. Breast care (Basel, Switzerland). 2017 Review GET IT
Times cited: 33
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. NPJ breast cancer. 2016 Academic Article GET IT
Times cited: 18
Therapies for triple negative breast cancer. Expert opinion on pharmacotherapy. 2015 Review GET IT
Times cited: 66
Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast cancer research : BCR. 2015 Academic Article GET IT
Times cited: 36
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer. Cancer investigation. 2014 Academic Article GET IT
Times cited: 11
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast cancer research and treatment. 2014 Academic Article GET IT
Times cited: 43
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 18
Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview. Current breast cancer reports. 2013 Academic Article GET IT
Times cited: 55
Breast cancer genomics: challenges in interpretation and application. The oncologist. 2013 Academic Article GET IT
Times cited: 1
Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer? 2012 GET IT
Times cited: 35
A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density. Anticancer research. 2012 Academic Article GET IT
Times cited: 13
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. International journal of cancer. 2011 Academic Article GET IT
Times cited: 184
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 99
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 Academic Article GET IT
Times cited: 442
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 23
Seeing red: anthracyclines for breast cancer. Oncology (Williston Park, N.Y.). 2011 Comment GET IT
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. International journal of cancer. 2010 Academic Article GET IT
Times cited: 90
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer chemotherapy and pharmacology. 2010 Academic Article GET IT
Times cited: 9
Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer. Anticancer research. 2010 Academic Article GET IT
Times cited: 18
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010 Academic Article GET IT
Times cited: 106
Incidence of and survival following brain metastases among women with inflammatory breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 28
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. The Lancet. Oncology. 2010 Academic Article GET IT
Times cited: 97
Circulating tumor cells as prognostic marker in metastatic breast cancer. Expert review of anticancer therapy. 2010 Review GET IT
Times cited: 28
Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. British journal of cancer. 2009 Academic Article GET IT
Times cited: 46
Circulating tumor cells in metastatic inflammatory breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 24
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 129
Patient characteristics and prognosis in metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Comment GET IT
Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Editorial Article GET IT
Times cited: 39
Documentation of complete response in metastatic breast cancer to liver and bone achieved with trastuzumab and pegylated liposomal Doxorubicin. 2008 GET IT
Times cited: 1
Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage. Personalized medicine. 2008 Academic Article GET IT
Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes. Clinical breast cancer. 2008 Review GET IT
Times cited: 11
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clinical breast cancer. 2007 Academic Article GET IT
Times cited: 24
Mucinous cancer of the appendix: challenges in diagnosis and treatment. 2007 GET IT
Times cited: 7
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 68
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 41
Primary mediastinal large B-cell lymphoma: clinical study of a distinct clinical entity and treatment outcome in 20 patients: review of the literature. American journal of clinical oncology. 2004 Review GET IT
Times cited: 5
Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clinical oncology (Royal College of Radiologists (Great Britain)). 2004 Academic Article GET IT
Times cited: 35
An overview of the status of imaging screening technology for breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Review GET IT
Times cited: 51
Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer research. 2002 Academic Article GET IT
Times cited: 18
G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer. 2001 Academic Article GET IT
Times cited: 13
Extensive lymphadenopathy as the first clinical manifestation in systemic lupus erythematosus. 2000 GET IT
Times cited: 26
Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecologic oncology. 1998 Academic Article GET IT
Times cited: 46
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Annals of oncology : official journal of the European Society for Medical Oncology. 1997 Academic Article GET IT
Times cited: 31
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology. 1997 Academic Article GET IT
Times cited: 28

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectory awarded by United States Department of Defense Co-Investigator 2021 - 2025
Converting HR+ Breast Cancer Into an Individualized Vaccine awarded by United States Department of Defense Co-Investigator 2019 - 2023

more ...

less ...

Background

education and training

D.Sc., University of Ioannina (Greece) 2000
M.D., University of Ioannina Medical School (Greece) 1994

Contact

full name

Eleni Andreopoulou

primary email

ela9082@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Eleni Andreopoulou Professor of Clinical Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage